Market Overview

Analyst Suggests MannKind Could Receive FDA Approval for Afrezza If Trials Pass


About one hour after the open MannKind (NASDAQ: MNKD) shares are trading down about 4 percent despite some bullish views from an analyst at Summer Street.

The analyst believes MannKind's new drug Afrezza is ready for approval by the FDA -- with one catch: the drug needs to pass two trials with flying colors.

The trials may show some risk of hypoglycemia and other cardiovascular risks, but won't consider pulmonary inflammation or lung cancer, according to the Summer Street analyst. Summer Street highlighted a survey taker suggesting there is an 85 percent chance Afrezza in type 1 diabetes will meet endpoint benchmarks of non-inferiority to injectable insulin.

Summer Street is "much more optimistic" on the current trials potentially allowing for FDA approval.

Latest Ratings for MNKD

May 2019Initiates Coverage OnBuy
Mar 2019Initiates Coverage OnOutperform
Feb 2019Initiates Coverage OnOutperform

View More Analyst Ratings for MNKD
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings Movers


Related Articles (MNKD)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: Bank of America Raises PT on Omnicare on Institutional Pharmacy Shake-Up

UPDATE: Goldman Sachs Raises PT on Rite Aid Following In-Line First Quarter Results